Abstract
INTRODUCTION
The apolipoprotein E (APOE) ε4 allele is a key genetic risk factor for Alzheimer’s disease (AD), but the etiology of impairment in non-carriers is less understood.
METHODS
We used regression and mediation models to test the cross-sectional relationships among APOE genotype, positron emission tomography amyloid and tau, vascular risk factors, and episodic memory within the US Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk ancillary imaging dataset of non-demented older adults.
RESULTS
In our cohort (N = 880), APOE ε4 carriers showed higher global amyloid, higher meta-temporal tau, smaller hippocampal volume, poorer memory, and a stronger relationship between amyloid and tau standardized uptake value ratio (SUVR; ∆β = 0.22, p < 0.001). Tau predicted memory (p < 0.01) and partially mediated the APOE–memory association. In a stratified analysis, higher Framingham Heart Study risk score (FHS; p = 0.022) and not tau SUVR (p = 0.1) were associated with memory among APOE ε4 non-carriers, whereas tau SUVR (p = 0.048) but not FHS risk score (p = 0.55) was associated with memory amongst APOE ε4 carriers.
DISCUSSION
Drivers of cognitive performance appear to be specific to APOE ε4 carrier status, emphasizing the need to identify alternative, or contributing, disease mechanisms among non-carriers.
Highlights

The US Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) cohort is composed of older adults at elevated risk of cognitive decline and cardiovascular disease burden.
Further multimodal neuroimaging data was collected through the POINTER Imaging ancillary study.
At baseline evaluation, the apolipoprotein E (APOE) ε4 genotype was significantly associated with amyloid and tau pathology, hippocampal atrophy, and poor episodic memory performance.
APOE ε4 genotype stratification analysis showed significant associations of Framingham cardiovascular risk score and smoking status with memory in non-carriers only.
Etiological pathways of dementia may differ in contributive strength to cognitive deterioration within this at-risk cohort.


If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.

This post is Copyright: | November 18, 2026
Neuro-Dementia